Mattress Liquidators has turned Entero Therapeutics white as a sheet. The creditor ordered Entero to repay its loan, prompting the biotech to lay off staff from the CEO down and race to find a way out of its predicament.
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset “ latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is ENTO effective May 17, 2024 ...
First Wave BioPharma Inc., a late clinical-stage biopharmaceutical company, has changed its name to Entero Therapeutics Inc. and unveiled a new website.
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion...
First Wave Announces Completion of Combination with ImmunogenX